根据前列腺特异性抗原值、临床肿瘤分期和格里森分级分组预测转移性前列腺癌的查找表的开发与验证
基于SEER数据库2010-2014年新诊断前列腺癌患者,利用PSA、临床肿瘤分期和格里森分级分组开发预测初诊时转移概率的查找表,在验证队列中预测准确率达94.3%(95%CI:94.2-94.3%)。该查找表可能作为基于高准确性和良好校准的临床工具有助于分期决策。
要点
- PSA>40ng/ml、GGG5和GGG4依次为转移性前列腺癌最强预测因素。
- 查找表在验证队列中预测转移概率的准确率为94.3%(95%CI:94.2-94.3%)。
- 校准图显示转移概率高达39.4%时模型预测准确,DCA净获益至阈值概率约54%。
核心结论
- 所提出的预测转移性前列腺癌概率的查找表基于其高准确性、良好校准和稳健的预测,可能代表一种有用的临床工具。
研究设计与样本
- 在监测、流行病学和最终结果数据库(2010-2014年)中识别新诊断前列腺癌且有临床肿瘤分期、PSA值和GGG的患者,按来源登记处随机分为开发队列(n=102469)和验证队列(n=98755)。
主要发现
- 201224例患者中3.5%患有转移性前列腺癌。
- PSA>40ng/ml、GGG5和GGG4依次为转移性前列腺癌最强预测因素。
- 在外部验证队列中,PSA、临床肿瘤分期和GGG预测转移性前列腺癌概率的准确率为94.3%(95%CI:94.2-94.3%)。
- 校准图显示转移概率高达39.4%时模型预测准确。
- 在DCA中,净获益记录至阈值概率约54%。
临床怎么用
- 原文未据此给出推荐,仅指出该查找表可能代表一种有用的临床工具,可用于分期决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) staging is crucial in clinical decision making and treatment assignment. OBJECTIVE: To develop a predictive tool that is capable of predicting the probability of metastases at initial PCa diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology, and End Results database (2010-2014), we identified patients with newly diagnosed PCa and available clinical tumor stage, prostatic-specific antigen value (PSA), and Gleason grade group (GGG), and with or without metastases. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We relied on PSA, clinical tumor stages, and GGG to discriminate between M1 and M0 patients. Patients were randomly divided according to the registry of origin between development (n=102469) and validation (n=98755) cohorts. Logistic regression modeling coefficients were used to devise a lookup table to discriminate between M0 and M1 stages. Receiver operating characteristic-derived area under the curve was tested for model accuracy, within the validation cohort. A total of 2000 bootstrap resamples were applied to 95% confidence intervals (CIs). Decision curve analysis (DCA) and calibration plots were used to test the performance of the lookup table. RESULTS AND LIMITATIONS: Of 201224 patients, 3.5% harbored metastatic PCa (mPCa). PSA >40ng/ml, GGG5, and GGG4, in that order, represented the strongest predictors of mPCa. Overall, PSA, clinical tumor stage, and GGG were 94.3% (95% CI: 94.2-94.3%) accurate in predicting the probability of mPCa, in the external validation cohort. Up to 39.4% probability of mPCa, the model demonstrated accurate predictions in the calibration plot. In DCA, a net benefit was recorded up to a threshold probability of approximately 54%. CONCLUSIONS: The proposed lookup table for the prediction of the probability of mPCa may represent a useful clinical tool based on its high accuracy, excellent calibration, and robust nature of predictions. PATIENT SUMMARY: Our study provides a highly accurate lookup table for the prediction of the probability of metastatic prostate cancer patients. This clinical tool can be useful in staging decisions.
引用
- Preisser F, Bandini M, Nazzani S, et al. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. Eur Urol Oncol. 2019. PMID: 31411975. doi:10.1016/j.euo.2019.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。